Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers N > Headlines for NPS Pharmaceuticals Inc. > News item |
NPS reiterated at buy by Jefferies
Jefferies & Co., Inc. analyst Adam Walsh reiterated NPS Pharmaceuticals, Inc. at buy on the company's underappreciated pipeline, and raised the 12-month price target to $7, from $6. Walsh believes that potential partnerships for Preos and Teduglutide could alleviate balance sheet concerns and renew interest in the company. Shares of the Salt Lake City-based pharmaceutical company were up 8 cents, or 1.78%, at $4.58. (Nasdaq: NPSP)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.